Ability of metformin to deplete NAD+ contributes to cancer cell susceptibility to metformin cytotoxicity and is dependent on NAMPT expression.

Zhuang, Yongxian; Haugrud, Allison B; Schaefer, Meg A; Messerli, Shanta M; Miskimins, W Keith

Zhuang, Yongxian; Haugrud, Allison B; Schaefer, Meg A; Messerli, Shanta M; Miskimins, W Keith.

Afiliação

Zhuang Y; Cancer Biology and Immunotherapies, Sanford Research, Sioux Falls, SD, United States.
Haugrud AB; Cancer Biology and Immunotherapies, Sanford Research, Sioux Falls, SD, United States.
Schaefer MA; Cancer Biology and Immunotherapies, Sanford Research, Sioux Falls, SD, United States.
Messerli SM; Sanford Program for Undergraduate Research (SPUR) Program, Sanford Research, Sioux Falls, SD, United States.
Miskimins WK; Cancer Biology and Immunotherapies, Sanford Research, Sioux Falls, SD, United States.

Front Oncol ; 13: 1225220, 2023.

Article em En | MEDLINE | ID: mdl-37583931

Palavras-chave

breast cancer; metformin; nicotinamide adenine dinucleotide (NAD+); nicotinamide phosphoribosyltransferase (NAMPT); tumorigenesis

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google